Cadila Healthcare Ltd - 532321 - USFDA Inspection Update
USFDA inspected the Company's formulations manufacturing facility located at Baddi from 15th to 19th July, 2019. At the end of the inspection, no observation (483) is issued.19-07-2019
19-07-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus' Nesher Pharmaceuticals receives final approval from the USFDA for Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate ER Capsules19-07-2019
It is unlikely for Zydus Cadila to repeat US feat this year, say analysts
Analysts doubt if other Indian firms in the segment will do much better in the formulations business in the US19-07-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces completion of enrollment in three Phase III trials of Saroglitazar Magnesium in NASH18-07-2019
CADILA HEALTHCARE LTD. - 532321 - AGM On August 9, 2019
Newspaper Advertisement relating to Notice of AGM, Remote e-voting and book closure.17-07-2019
Cadila Healthcare Ltd - 532321 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended On June 30, 2019
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2019 ,inter alia, to consider and approve Amongst other agenda items, Unaudited Financial Results for the quarter ended on June 30, 201916-07-2019
Cadila Healthcare Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate15-07-2019
CADILA HEALTHCARE LTD. - 532321 - Reg. 34 (1) Annual Report
Annual Report for the financial year 2018-201913-07-2019
CADILA HEALTHCARE LTD. - 532321 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- Dhaval N. SoniDesignation :- Company Secretary and Compliance Officer08-07-2019
Cadila Healthcare: In bad shape - Sell
USFDA observations on contamination at a plant, and lack of near-term blockbuster products have taken a toll on the stock07-07-2019